---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-24-000034"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2024-05-23T23:59:59+00:00"
generated_at: "2026-06-01T09:07:06.263629+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Supernus reports positive interim Phase 2a data for SPN-817 in treatment-resistant seizures

## Summary
- 75% median focal seizure reduction at 3-4 mg BID in maintenance period; 86% reduction in open-label extension.
- 81% of focal-seizure subjects had ≥30% reduction; 63% had ≥50% reduction in maintenance period.
- Discontinuation rate due to AEs was 22% in titration and 2.4% in maintenance; common AEs: nausea, diarrhea, headache.
- Company plans to initiate Phase 2b study before year-end 2024; full Phase 2a topline results expected H2 2024.
- CEO states interim data provide strong evidence of clinical utility and potential differentiated treatment option.

## SEC filing metadata
- accession: 0001356576-24-000034
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2024-05-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000034/0001356576-24-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000034/supn-20240523.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-24-000034
- JSON: https://secwatch.observer/filing/0001356576-24-000034.json
- Plain text: https://secwatch.observer/filing/0001356576-24-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.